SURVYR

CTNM

Contineum Therapeutics, Inc.
$9.15
+$0.16 (1.78%)Oct 28 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-40%-15%+9%+34%+59%Oct 2025Oct 2026Apr 202652w high $17.7952w low $6.72
CTNMSPY
Wall St. Highest PT $30.00 (+227.9%) Wall St. Avg PT $22.14 (+142.0%)
$7$16$24$33$41POC $13Hi $30Avg $22
Underwater Drawdown %Max DD -59.7%Current -47.9%
0.0%-59.7%
Relative Strength vs SPY-32.3% vs SPYUnderperforming
+57%0%-57%
1W
+$0.80 (9.58%)
1M
−$3.58 (28.12%)
3M
−$5.23 (36.37%)
6M
−$2.89 (24.00%)
YTD
−$2.28 (19.95%)
1Y
−$1.88 (17.04%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
7 analysts · mean score 1.62
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$9.15
Average target$22.14
+$12.99 (+142.0%) upsideaverage target vs current price
CurrentAverageMedian
Low$14.00
Median$22.14
High$30.00
12-month Wall Street target range
Recent analyst rating changes · 8
Reiterated
2026-10-15 · Jones Trading reiterated Buy on CTNM
Downgrade
2026-10-14 · Baird downgraded CTNM from Outperform to Neutral
Reiterated
2026-09-28 · Morgan Stanley reiterated Equal-Weight on CTNM
Reiterated
2026-09-15 · Jones Trading reiterated Buy on CTNM
Reiterated
2026-09-15 · Baird reiterated Outperform on CTNM
Reiterated
2026-07-31 · RBC Capital reiterated Outperform on CTNM
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$313.9M
P/E (next 12 months, estimated)-4.3
52-week range$6.72 – $17.79
Dividend yieldNo dividend
Analyst consensusBuy (7)
Average analyst price target$22.14 (+142%)

What they do

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for CTNM yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

CTNM earningsReports tomorrow
Next report · quarter Sep 2026
Thu Oct 29, 2026After the close
EPS consensus-$0.45 range -$0.51–-$0.40
Revenue consensus$0 6 analysts
Last 4 quarters · EPS vs estimate
Jul 30, 2026-$0.40est -$0.45+10.8%Above estimates
May 5, 2026-$0.39est -$0.53+26.6%Above estimates
Mar 5, 2026-$0.49est -$0.39−26.1%Below estimates
Oct 30, 2025-$0.45est -$0.46+1.6%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-21 12:16:56 ET
24-1125-0325-0525-0825-1026-0326-0526-07-0.620.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$0–
2026-03-31$0–
2025-12-31$0–
2025-09-30$0–
2025-06-30$0–

News & catalysts

More news
BMY Reports Mixed Phase III Trial Results, Stock Down
Zacks · Oct 13
Baird Downgrades Contineum Therapeutics to Neutral From Outperform, Price Target is $14
MT Newswires · Oct 13
Bristol Myers Reverses Lower Despite Double Phase 3 Win, As A Key Rival Crashes
Investor's Business Daily · Oct 12
Bristol Myers Stock Tumbles on ‘Confounding’ Trial Results
Barrons.com · Oct 12
All You Need to Know About Contineum Therapeutics, Inc. (CTNM) Rating Upgrade to Buy
Zacks · Oct 12
Rating changes
Reiterated
2026-10-15 · Jones Trading reiterated Buy on CTNM
Downgrade
2026-10-14 · Baird downgraded CTNM from Outperform to Neutral
Reiterated
2026-09-28 · Morgan Stanley reiterated Equal-Weight on CTNM
Reiterated
2026-09-15 · Jones Trading reiterated Buy on CTNM
Reiterated
2026-09-15 · Baird reiterated Outperform on CTNM
Reiterated
2026-07-31 · RBC Capital reiterated Outperform on CTNM

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Stengone Carmine N.
Director, CEO and President · 2026-09-08
Sell
$41.1K
Stengone Carmine N.
Director, CEO and President · 2026-08-03
Sell
$40.0K

Stats refreshed 2026-10-21 12:16:56 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026